Have a feature idea you'd love to see implemented?
Let us know!
ABEO Abeona Therapeutics Inc
Price (delayed)
$6.34
Market cap
$274.61M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.09
Enterprise value
$263.01M
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
Highlights
The company's quick ratio has surged by 63% YoY and by 36% QoQ
ABEO's EPS is up by 35% since the previous quarter but it is down by 8% year-on-year
Abeona Therapeutics's net income has decreased by 34% YoY but it has increased by 31% QoQ
The company's gross profit has shrunk by 100% QoQ and by 100% YoY
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Key stats
What are the main financial stats of ABEO
Market
Valuations
Earnings
Shares outstanding
43.31M
Market cap
$274.61M
Enterprise value
$263.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$50.36M
EBITDA
-$47.48M
Free cash flow
-$43.68M
Per share
Balance sheet
Liquidity
EPS
-$2.09
Free cash flow per share
-$1.09
Book value per share
$1.78
Revenue per share
$0
TBVPS
$3.35
Total assets
$134M
Total liabilities
$60.76M
Debt
$23.17M
Equity
$73.24M
Working capital
$109.06M
Debt to equity
0.32
Current ratio
7.48
Quick ratio
7.4
Net debt/EBITDA
0.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-62.1%
Return on equity
-207.9%
Return on invested capital
-73.7%
Return on capital employed
-43%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABEO stock price
How has the Abeona Therapeutics stock price performed over time
Intraday
1.44%
1 week
-5.93%
1 month
10.07%
1 year
58.5%
YTD
26.55%
QTD
0.32%
Financial performance
How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$56.71M
Net income
-$52.6M
Gross margin
N/A
Net margin
N/A
The company's gross profit has shrunk by 100% QoQ and by 100% YoY
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Abeona Therapeutics's net income has decreased by 34% YoY but it has increased by 31% QoQ
The operating income has decreased by 31% YoY and by 19% from the previous quarter
Growth
What is Abeona Therapeutics's growth rate over time
Valuation
What is Abeona Therapeutics stock price valuation
P/E
N/A
P/B
3.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ABEO's EPS is up by 35% since the previous quarter but it is down by 8% year-on-year
The price to book (P/B) is 43% higher than the 5-year quarterly average of 2.5
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Efficiency
How efficient is Abeona Therapeutics business performance
Abeona Therapeutics's return on equity has surged by 75% QoQ and by 7% YoY
The company's return on assets rose by 48% QoQ and by 17% YoY
The company's return on invested capital rose by 48% QoQ and by 22% YoY
Dividends
What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABEO.
Financial health
How did Abeona Therapeutics financials performed over time
The company's total assets is 121% higher than its total liabilities
The company's total assets has surged by 150% YoY and by 79% QoQ
The company's quick ratio has surged by 63% YoY and by 36% QoQ
Abeona Therapeutics's debt is 68% lower than its equity
Abeona Therapeutics's debt to equity has surged by 112% QoQ but it has shrunk by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.